Friday, April 01, 2022 8:21:19 AM
As previously disclosed, on September 16, 2020, VBI Vaccines Inc. (the “Company”), as guarantor, and Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of the Company (“Variation”), as the recipient, entered into a Contribution Agreement (the “Agreement”) with Her Majesty The Queen in Right of Canada, as represented by the Minister of Industry (the “Minister”), pursuant to which Variation is obligated to develop a novel, broadly reactive coronavirus vaccine against SARS-COV2 (“COVID-19”), Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome, and/or a monovalent vaccine targeting only COVID-19 through Phase 2 studies (such undertaking, the “Project”). Pursuant to the Agreement, the Company agreed to complete the Project in or before the first quarter of 2022 (the “Project Completion Date”), which will be conducted exclusively in Canada, except as permitted otherwise under certain circumstances.
On March 28, 2022, the Company and the Minister signed an amendment (the “Amendment”) to the Agreement, the main purpose of which was to extend the collaboration and move the Project Completion Date from March 31, 2022 to December 31, 2023.
Recent VBIV News
- VBI Vaccines Reports Full Year 2023 Financial Results • Business Wire • 04/16/2024 12:00:00 PM
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/11/2024 08:05:00 PM
- VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/09/2024 06:45:00 PM
- VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma • Business Wire • 04/03/2024 12:00:00 PM
- VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform • Business Wire • 04/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:34:40 PM
- VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences • Business Wire • 02/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:23:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:00:27 PM
- VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:07:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:06:26 PM
- VBI Vaccines Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:00:33 PM
- VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program • Business Wire • 10/26/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:30:36 AM
- VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern • Business Wire • 09/27/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 12:00:40 PM
- VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM • Business Wire • 09/07/2023 12:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM